

**eTable 1. Characteristics of Patients from Fudan University Shanghai Cancer Center**

Characteristic		Total=335	
		n	%
Age	≤50	208	62.1
	>50	127	37.9
Neoadjuvant chemotherapy cycle	2-3	234	69.9
	4-6	101	30.1
Tumor size before neoadjuvant chemotherapy	40-60 mm	142	42.4
	60-80 mm	193	57.6
Lymph node status	Negative*	73	21.8
	Positive*	262	78.2
pCR in breast	Non-pCR	303	90.4
	pCR	32	9.6
pCR in breast and nodes	Non-pCR	315	94.0
	pCR	20	6.0
Grade	I	3	1.5
	II	135	69.2
	III	57	29.2
	Unknown	140	
ER (before neoadjuvant chemotherapy)	Negative	88	56.8
	Positive	67	43.2
	Unknown	180	
ER (after surgery)	negative	177	60.8
	Positive	114	39.2
	Unknown	44	
PR (before neoadjuvant chemotherapy)	Negative	90	58.1
	Positive	65	41.9
	Unknown	180	
PR (after surgery)	negative	189	64.9
	Positive	102	35.1
	Unknown	44	
HER2 (before neoadjuvant chemotherapy)	Negative	104	68.0
	Positive	49	32.0
	Unknown	182	
HER2 (after surgery)	negative	215	74.7
	Positive	73	25.3
	Unknown	47	
Adjuvant chemotherapy	No	27	8.1
	Yes	308	91.9
Adjuvant radiotherapy	No	46	13.7
	Yes	289	86.3
Adjuvant endocrine therapy	No	187	55.8
	Yes	148	44.2

\*Lymph node (LN) negative cases represent patients with both clinically detected LN-negative before NCT and pathologically confirmed LN-negative after surgery; LN positive cases represent patients with either clinically detected LN-positive before NCT or pathologically confirmed LN-positive after surgery. "Clinically detected" is defined as detected by imaging studies or by clinical examination and having characteristics highly suspicious for involved LN or a presumed pathologic macro-metastasis based on fine needle aspiration biopsy with cytologic examination.